The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626001075370p
Ethics application status
Help: Ethics application status
Submitted, not yet approved
Date submitted
Help: Date submitted
24/06/2026
Date registered
Help: Date registered
1/09/2026
Date last updated
Help: Date last updated
1/09/2026
Date data sharing statement initially provided
Help: Data sharing statement date
1/09/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Assess the validity of using fluorescent imaging of indocyanine free dye in stool (nappy) in checking if bile duct/system is patent in infants with jaundice and pale stool as screening for biliary atresia.
Scientific title
Validating the use of fluorescent imaging of indocyanine green in stool in confirming biliary patency (patent biliary system) in infants with cholestasis.
Additional trial identifiers [1] 317788 0
Nil
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Neonatal Cholestasis 342495 0
Condition category
Condition code
Oral and Gastrointestinal 338622 338622 0 0
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
The intervention is to inject TGA approved indocyanine green dye intravenously into neonates with cholestasis and utilise bedside flourescence imaging of the stools to detect the ICG dye presence in the stool to confirm biliary patency.

Dose of Dye will be 0.1mg/kg through intravenous catheter (IVC) once only.
Dye will be injected by beside nursing staff as per pharmacy instructions and the nappies will be collected and viewed by trained investigators using the IC-flow hand held ICG detection camera. All nappies following the intravenous dye injection will be collected for 7 days.

The intervention will be performed in the neonatal intensive care unit in babies with cholestasis who will also be undergoing standard investigations for biliary atresia (liver ultrasound and scuntigraphy)
Intervention code [1] 334514 0
Diagnosis / Prognosis
Description of the comparator or control
This is a validation study comparing the current "best available" liver scintigraphy (HIDA) scan to the ICG stool detection within the same patient.
There is no direct control group.
We are currently doing a retrospective audit of number of patients with cholestasis and needed repeated testing, unnecessary transfer to tertiary children's hospital, as your baseline review. The data will come from medical record over 5 year period (Jan 2021-Current August 2026).
Control group
Active

Outcomes
Primary outcome [1] 345891 0
Sensitivity: Proportion of neonates with biliary atresia correctly identified by positive ICG stool fluorescence test
Timepoint [1] 345891 0
Collection of all stooled nappies for 7 days post ICG injection. Nappies will be assessed every 24 hours, with specific time recorded to correlate to time of injection. We aim to collect this for up to 7 days as end point - if there is no excretion of dye by then, refer patient to children's hospital for more definitive testing such as DISIDA or intraoperative cholangiogram.
Primary outcome [2] 346169 0
Specificity: Proportion of neonates with patent biliary systems correctly identified by negative ICG stool fluorescence test, comparing to reference standard listed above
Timepoint [2] 346169 0
Collection of all stooled nappies for 7 days post ICG injection. Nappies will be assessed every 24 hours, with specific time recorded to correlate to time of injection. We aim to collect this for up to 7 days as end point - if there is no excretion of dye by then, refer patient to children's hospital for more definitive testing such as DISIDA or intraoperative cholangiogram.
Secondary outcome [1] 463724 0
Time from ICG administration to first positive fluorescence detection.
Timepoint [1] 463724 0
Collection of all stooled nappies for 7 days post ICG injection. Nappies will be assessed every 24 hours, with specific time recorded to correlate to time of injection.
Secondary outcome [2] 464878 0
Optimal stool collection timepoint (6h, 12h, 24h, or 48h post-ICG).
Timepoint [2] 464878 0
Collection of all stooled nappies for 7 days post ICG injection. Nappies will be assessed every 24 hours, with specific time recorded to correlate to time of injection.
Secondary outcome [3] 466067 0
Proportion of planned stool collections successfully obtained.
Timepoint [3] 466067 0
Nappies will be assessed every 24 hours for 7 days from time of injection. A record charts of soiled nappies will also be collected simultaneously by nursing staff or carer eg parents.
Secondary outcome [4] 466068 0
Incidence and severity of adverse effects from ICG - related adverse events in neonates. This will be assessed as composite result.
Timepoint [4] 466068 0
Up to 7 days from injection.

Eligibility
Key inclusion criteria
1. Neonates admitted to the NICU / SCN up to 3 months corrected gestational age
2. Presenting with cholestasis defined as conjugated bilirubin >20 µmol/L or >20% of total bilirubin
3. Undergoing investigation for cause of cholestasis
4. Parent/guardian able to provide informed consent
5. Expected to remain in NICU or under care at study site for duration of diagnostic workup
Minimum age
No limit
Maximum age
6 Months
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
1. Known hypersensitivity to ICG or iodine
2. Known or suspected thyroid disease
3. Previous administration of ICG within 2 weeks
4. Already definitively diagnosed prior to enrolment
5. Concomitant gastrointestinal pathology that may interfere with stool collection or interpretation (e.g., intestinal obstruction, necrotizing enterocolitis, inflammatory bowel disease)
6. Severe haemodynamic instability as determined by treating neonatologist (e.g., requiring high-frequency ventilation, requiring >2 inotropes, severe hypotension unresponsive to treatment)
7. Parent/guardian unable or unwilling to provide informed consent
8. Neonates receiving palliative care or with life-limiting conditions where diagnostic workup would not alter management
9. Nil by mouth status with absent stool output

Study design
Purpose of the study
Diagnosis
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Other
Other design features
All participants meeting inclusion criteria will receive same interventions - both ICG dye and liver scintigraphy.
Phase
Not Applicable
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis
As a validation study, all patients undergoing investigation for possible biliary atresia with neonatal cholestasis will be included for a 12 month period. All patients will undergo standard diagnostic investigation (liver ultrasound, HIDA scan) in parallel to the ICG dye testing and the results of the ICG dye testing will be compared to the HIDA scan results, as well as to disHIDA scanning / intraoperative cholangiogram where able.

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
ACT
Recruitment hospital [1] 29706 0
The Canberra Hospital - Garran
Recruitment postcode(s) [1] 46054 0
2605 - Garran

Funding & Sponsors
Funding source category [1] 322197 0
Self funded/Unfunded
Name [1] 322197 0
Country [1] 322197 0
Primary sponsor type
Hospital
Name
Canberra Health Servives
Address
Country
Australia
Secondary sponsor category [1] 325138 0
Individual
Name [1] 325138 0
Dr Pearl Chan, Canberra Hospital Department of Paediatrics
Address [1] 325138 0
Country [1] 325138 0
Australia
Secondary sponsor category [2] 325139 0
Individual
Name [2] 325139 0
Dr Tejasvi Chaudhari, Canberra Hospital Department of Neonatology
Address [2] 325139 0
Country [2] 325139 0
Australia
Other collaborator category [1] 284005 0
Individual
Name [1] 284005 0
Dr Dana Mooney Canberra Hospital Department of Paediatrics
Address [1] 284005 0
Country [1] 284005 0
Australia

Ethics approval
Ethics application status
Submitted, not yet approved
Ethics committee name [1] 320721 0
ACT Health Human Research Ethics Committee
Ethics committee address [1] 320721 0
Ethics committee country [1] 320721 0
Australia
Date submitted for ethics approval [1] 320721 0
29/06/2026
Approval date [1] 320721 0
Ethics approval number [1] 320721 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 151410 0
Dr Pearl Chan
Address 151410 0
Centenary Hospital for Women and Children, Yamba Drive, Garran, ACT, 2605
Country 151410 0
Australia
Phone 151410 0
+61400851675
Fax 151410 0
Email 151410 0
Contact person for public queries
Name 151411 0
Pearl Chan
Address 151411 0
Centenary Hospital for Women and Children, Yamba Drive, Garran, ACT, 2605
Country 151411 0
Australia
Phone 151411 0
+61400851675
Fax 151411 0
Email 151411 0
Contact person for scientific queries
Name 151412 0
Pearl Chan
Address 151412 0
Centenary Hospital for Women and Children, Yamba Drive, Garran, ACT, 2605
Country 151412 0
Australia
Phone 151412 0
+61400851675
Fax 151412 0
Email 151412 0

Data sharing statement
Will the study consider sharing individual participant data?
No
No IPD sharing reason/comment: Individual data not clinically useful in a validation trial



What supporting documents are/will be available?

TypeCitationLinkEmailOther DetailsAttachment
Study protocol    Study Protocol _ ICG BA Neonates.pdf


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.